Completed PHASE3 INTERVENTIONAL 2-arm NCT01454739

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A

Sponsor: Bioverativ Therapeutics Inc.

Conditions Hemophilia A

Interventions rFVIIIFc

Updated 12 times since 2017 Last updated: Dec 16, 2020 Started: Dec 31, 2011 Primary completion: Oct 31, 2017 Completion: Oct 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Hemophilia A and is currently completed. Bioverativ Therapeutics Inc. leads this study, which shows 12 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Dec 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jun 2018 — Dec 2018 [monthly]

Completed PHASE3
Jan 2018 — Jun 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Oct 2017 — Jan 2018 [monthly]

Active Not Recruiting PHASE3

Status: Enrolling By Invitation → Active Not Recruiting
Jun 2017 — Oct 2017 [monthly]

Enrolling By Invitation PHASE3
Mar 2017 — Jun 2017 [monthly]

Enrolling By Invitation PHASE3
Feb 2017 — Mar 2017 [monthly]

Enrolling By Invitation PHASE3
Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE3

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioverativ Therapeutics Inc.

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Auckland, New Zealand , Bangalore, India , Barcelona, Spain , Basingstoke, United Kingdom , Berlin, Germany , Bonn, Germany , Boston, United States , Bron, France , Brussels, Belgium and 59 more locations